Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy

Kazuhiko Nakamura, Kazuya Akahoshi, Toshiaki Ochiai, Keishi Komori, Kazuhiro Haraguchi, Munehiro Tanaka, Norimoto Nakamura, Yoshimasa Tanaka, Kana Kakigao, Haruei Ogino, Eikichi Ihara, Hirotada Akiho, Yasuaki Motomura, Teppei Kabemura, Naohiko Harada, Yoshiharu Chijiiwa, Tetsuhide Ito, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.

元の言語英語
ページ(範囲)423-426
ページ数4
ジャーナルGut and Liver
6
発行部数4
DOI
出版物ステータス出版済み - 10 1 2012

Fingerprint

Peptic Ulcer
Group Psychotherapy
Anti-Inflammatory Agents
Drug Therapy
Non-Steroidal Anti-Inflammatory Agents
Hemoglobins
Endoscopic Hemostasis
Hemorrhage
Digestive System Endoscopy
Fibrinolytic Agents
Endoscopy
Medical Records
Control Groups
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

これを引用

Nakamura, K., Akahoshi, K., Ochiai, T., Komori, K., Haraguchi, K., Tanaka, M., ... Takayanagi, R. (2012). Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy. Gut and Liver, 6(4), 423-426. https://doi.org/10.5009/gnl.2012.6.4.423

Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy. / Nakamura, Kazuhiko; Akahoshi, Kazuya; Ochiai, Toshiaki; Komori, Keishi; Haraguchi, Kazuhiro; Tanaka, Munehiro; Nakamura, Norimoto; Tanaka, Yoshimasa; Kakigao, Kana; Ogino, Haruei; Ihara, Eikichi; Akiho, Hirotada; Motomura, Yasuaki; Kabemura, Teppei; Harada, Naohiko; Chijiiwa, Yoshiharu; Ito, Tetsuhide; Takayanagi, Ryoichi.

:: Gut and Liver, 巻 6, 番号 4, 01.10.2012, p. 423-426.

研究成果: ジャーナルへの寄稿記事

Nakamura, K, Akahoshi, K, Ochiai, T, Komori, K, Haraguchi, K, Tanaka, M, Nakamura, N, Tanaka, Y, Kakigao, K, Ogino, H, Ihara, E, Akiho, H, Motomura, Y, Kabemura, T, Harada, N, Chijiiwa, Y, Ito, T & Takayanagi, R 2012, 'Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy', Gut and Liver, 巻. 6, 番号 4, pp. 423-426. https://doi.org/10.5009/gnl.2012.6.4.423
Nakamura, Kazuhiko ; Akahoshi, Kazuya ; Ochiai, Toshiaki ; Komori, Keishi ; Haraguchi, Kazuhiro ; Tanaka, Munehiro ; Nakamura, Norimoto ; Tanaka, Yoshimasa ; Kakigao, Kana ; Ogino, Haruei ; Ihara, Eikichi ; Akiho, Hirotada ; Motomura, Yasuaki ; Kabemura, Teppei ; Harada, Naohiko ; Chijiiwa, Yoshiharu ; Ito, Tetsuhide ; Takayanagi, Ryoichi. / Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy. :: Gut and Liver. 2012 ; 巻 6, 番号 4. pp. 423-426.
@article{8a829c97de9f439c996d61862be9e7ec,
title = "Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy",
abstract = "Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.",
author = "Kazuhiko Nakamura and Kazuya Akahoshi and Toshiaki Ochiai and Keishi Komori and Kazuhiro Haraguchi and Munehiro Tanaka and Norimoto Nakamura and Yoshimasa Tanaka and Kana Kakigao and Haruei Ogino and Eikichi Ihara and Hirotada Akiho and Yasuaki Motomura and Teppei Kabemura and Naohiko Harada and Yoshiharu Chijiiwa and Tetsuhide Ito and Ryoichi Takayanagi",
year = "2012",
month = "10",
day = "1",
doi = "10.5009/gnl.2012.6.4.423",
language = "English",
volume = "6",
pages = "423--426",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "4",

}

TY - JOUR

T1 - Characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy

AU - Nakamura, Kazuhiko

AU - Akahoshi, Kazuya

AU - Ochiai, Toshiaki

AU - Komori, Keishi

AU - Haraguchi, Kazuhiro

AU - Tanaka, Munehiro

AU - Nakamura, Norimoto

AU - Tanaka, Yoshimasa

AU - Kakigao, Kana

AU - Ogino, Haruei

AU - Ihara, Eikichi

AU - Akiho, Hirotada

AU - Motomura, Yasuaki

AU - Kabemura, Teppei

AU - Harada, Naohiko

AU - Chijiiwa, Yoshiharu

AU - Ito, Tetsuhide

AU - Takayanagi, Ryoichi

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.

AB - Background/Aims: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. Methods: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. Results: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. Conclusions: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.

UR - http://www.scopus.com/inward/record.url?scp=84868122198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868122198&partnerID=8YFLogxK

U2 - 10.5009/gnl.2012.6.4.423

DO - 10.5009/gnl.2012.6.4.423

M3 - Article

VL - 6

SP - 423

EP - 426

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 4

ER -